Immunocore Holdings PLC
IMCR33.085USD
+0.095+0.29%
Market hours （ET）Quotes delayed by 15 min
1.66BMarket Cap
LossP/E TTM
More Details of Immunocore Holdings PLC Company
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Company Info
Ticker SymbolIMCR
Company nameImmunocore Holdings PLC
IPO dateFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Number of employees493
Security typeDepository Receipt
Fiscal year-endFeb 05
Address92 Park Drive Milton Park
CityABINGDON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeOX14 4RY
Phone441235438600
Websitehttps://www.immunocore.com/
Ticker SymbolIMCR
IPO dateFeb 05, 2021
CEODr. Bahija Jallal, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Siddharth Kaul
Mr. Siddharth Kaul
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Prof. Peter Ratcliffe
Prof. Peter Ratcliffe
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Prof. John Bell
Prof. John Bell
Independent Chairman of the Board
Independent Chairman of the Board
13.45K
--
Mr. Roy S. Herbst, M.D., Ph.D.
Mr. Roy S. Herbst, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Clayton Robertson
Mr. Clayton Robertson
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Bahija Jallal, Ph.D.
Dr. Bahija Jallal, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Tina St. Leger
Ms. Tina St. Leger
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. William Pao, M.D., Ph.D.
Dr. William Pao, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2023Q3
FY2023Q2
FY2022
FY2022Q3
FY2022Q2
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
226.69M
73.08%
Europe
73.22M
23.61%
International
10.08M
3.25%
Collaboration revenue
213.00K
0.07%
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Shareholders
Shareholders
Proportion
T. Rowe Price Investment Management, Inc.
14.25%
Wellington Management Company, LLP
12.39%
RTW Investments L.P.
9.84%
Fidelity Management & Research Company LLC
9.71%
PRIMECAP Management Company
5.41%
Other
48.41%
Shareholder Types
Shareholders
Proportion
Investment Advisor
41.30%
Investment Advisor/Hedge Fund
26.52%
Hedge Fund
22.94%
Corporation
5.15%
Private Equity
3.16%
Research Firm
2.66%
Pension Fund
0.42%
Bank and Trust
0.25%
Venture Capital
0.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
292
50.72M
102.46%
-9.05M
2025Q1
304
50.82M
102.67%
-9.36M
2024Q4
304
48.99M
99.30%
-7.33M
2024Q3
299
49.26M
99.94%
-5.38M
2024Q2
298
47.15M
96.58%
+1.62M
2024Q1
283
47.77M
97.93%
+3.51M
2023Q4
262
40.76M
86.07%
-2.70M
2023Q3
246
44.95M
95.97%
-1.86M
2023Q2
236
43.68M
94.12%
-435.38K
2023Q1
218
40.62M
88.44%
-3.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
T. Rowe Price Investment Management, Inc.
7.05M
14.25%
+351.61K
+5.25%
Mar 31, 2025
Wellington Management Company, LLP
6.13M
12.39%
-485.33K
-7.33%
Mar 31, 2025
RTW Investments L.P.
4.87M
9.84%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
9.71%
+23.88K
+0.50%
Mar 31, 2025
PRIMECAP Management Company
2.68M
5.41%
+10.10K
+0.38%
Mar 31, 2025
Eli Lilly Vostok SA Geneva
2.55M
5.15%
--
--
Mar 21, 2025
Baker Bros. Advisors LP
2.32M
4.69%
+807.34K
+53.28%
Mar 31, 2025
Tang Capital Management, LLC
1.92M
3.87%
+360.11K
+23.15%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.89M
3.81%
-299.59K
-13.70%
Mar 31, 2025
Kynam Capital Management LP
1.70M
3.43%
+470.00K
+38.35%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
1.7%
Tema Oncology ETF
1.18%
ALPS Medical Breakthroughs ETF
1.07%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.1%
iShares Intl Small Cap Equity Factor ETF
0.09%
Fidelity Nasdaq Composite Index ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
View more
Virtus LifeSci Biotech Products ETF
Proportion1.7%
Tema Oncology ETF
Proportion1.18%
ALPS Medical Breakthroughs ETF
Proportion1.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
SPDR S&P International Small Cap ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.1%
iShares Intl Small Cap Equity Factor ETF
Proportion0.09%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
SPDR Portfolio Developed World ex-US ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
